DYAI
DYADIC INTERNATIONAL INC
$0.7376
+2.44%
$26.3M
No data for this timeframe.
Vol
Market Cap$26.3M
Cap SizeNano Cap
Inst. Holders5 funds
Inst. Value$999.2K
Inst. Activity0 buys / 1 sells
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001213809·Prev Close $0.7200
Recent Activity
Inst.
MORGAN STANLEY — NEAR_EXIT
227 shares ($213.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
165,100 shares ($194.8K)
May 19, 2026
other
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Mar 25, 2026
Press
Dyadic International reported its 2025 financial results, showing a decline in total revenue to $3.09 million from $3.50
Impact 5/10
Mar 16, 2026
Press
Dyadic International has entered into an OEM distribution agreement with IBT Bioservices to commercialize Dyadic's recom
Impact 5/10
Price Targets
Historical data — last covering-analyst action Nov 2024. No current recommendation available.
$6.00 (Nov 2024)
Current $0.7376
Low $5.00
Median $6.00
High $7.00
2 analysts
$5.00
$7.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jul 8, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 13, 2023 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 24, 2023 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 3, 2023 | HC Wainwright & Co. | REITERATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.04 ▲ +8.3% | $-0.04 — $-0.03 | 39% YoY | 3 |
| Next Q | $-0.04 ▲ +8.3% | $-0.05 — $-0.03 | 39% YoY | 3 |
| Current FY | $-0.10 ▼ -6.9% | $-0.13 — $-0.07 | 55% YoY | 3 |
| Next FY | $0.03 ▲ +233.3% | $-0.08 — $0.17 | 132% YoY | 3 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $860.1K | — |
| RENAISSANCE TECHNOLOGIES LLC | $138.8K | DOUBLED |
| MORGAN STANLEY | $213.00 | NEAR_EXIT |
| WELLS FARGO & COMPANY/MN | $168.00 | — |
| BANK OF AMERICA CORP | $16.00 | NEAR_EXIT |
5 institutional holders with $999.2K total value (1,062,997 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 914,960 | $860.1K | 86.1% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 147,615 | $138.8K | 13.9% | DOUBLED +246.8% |
| 3 | MORGAN STANLEY | 227 | $213.00 | 0.0% | NEAR_EXIT -95.8% |
| 4 | WELLS FARGO & COMPANY/MN | 178 | $168.00 | 0.0% | — |
| 5 | BANK OF AMERICA CORP /DE/ | 17 | $16.00 | 0.0% | NEAR_EXIT -92.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | NEAR_EXIT | 5,427 | 227 | -95.8% | $213.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 47,605 | 165,100 | +246.8% | $194.8K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 203 | 15 | -92.6% | $18.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 30,976 | 47,605 | +53.7% | $47.1K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 16,336 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | NEW | — | 13,500 | — | $18.2K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 12,254 | 5,654 | -53.9% | $9.9K | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 28,511 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 16,336 | — | $17.0K | 2024-Q3 |
| MORGAN STANLEY | DOUBLED | 454 | 12,254 | +2599.1% | $12.7K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
MIXED
5/10
Dyadic International reported its 2025 financial results, showing a decline in total revenue to $3.0
Mar 25, 2026
MIXED
5/10
Dyadic International has entered into an OEM distribution agreement with IBT Bioservices to commerci
Mar 16, 2026
NEUTRAL
4/10
Dyadic International and Fermbox Bio announced the commercial launch of animal-origin-free Recombina
Mar 4, 2026
Historical analyst distribution (last covering-analyst action Nov 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2024. No current recommendation available.
$6.00 mean target (Nov 2024)
$5.00 Low
$7.00 High
| Metric | Value |
|---|---|
| Current Price | $0.7376 |
| Target Low | $5.00 |
| Target Mean | $6.00 |
| Target Median | $6.00 |
| Target High | $7.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.04 | $-0.04 | $-0.03 | 38.9% | +8.3% | — | $0.0B | 6.1% | 3 |
| Next Q 2026-09-30 |
$-0.04 | $-0.05 | $-0.03 | 38.9% | +8.3% | 1↑ 0↓ | $0.0B | 29.5% | 3 |
| Current FY 2026-12-31 |
$-0.10 | $-0.13 | $-0.07 | 55.1% | -6.9% | 0↑ 1↓ | $0.0B | 126.9% | 3 |
| Next FY 2027-12-31 |
$0.03 | $-0.08 | $0.17 | 132.3% | +233.3% | — | $0.0B | 88.6% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.037 | |
| 7d ago | $-0.040 | +0.003 |
| 30d ago | $-0.040 | +0.003 |
| 60d ago | $-0.040 | +0.003 |
| 90d ago | $-0.040 | +0.003 |
2 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jul 8, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 24, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 3, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Jul 18, 2022 | Dawson James | DOWNGRADE | Buy | Neutral |
| Apr 5, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Dec 17, 2021 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 19, 2026
other
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
May 13, 2026
earnings
Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
DYADIC ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND
HIGHLIGHTS RECENT COMPANY PROGRESS
May 13, 2026
earnings_calendar
DYAI Q1 2026 Earnings Scheduled — 2026-05-13
May 7, 2026
earnings_calendar
DYAI Q1 2026 Earnings Scheduled — 2026-05-07
Mar 25, 2026
earnings
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
DYADIC ANNOUNCES 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS
Mar 25, 2026
earnings_calendar
DYAI Q4 2025 Earnings After Market Close — 2026-03-25
Mar 16, 2026
contract
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
Mar 11, 2026
earnings
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
Dyadic to Report Year 2025 Financial Results
Mar 4, 2026
contract
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration:
Animal-Origin-Free Recombinant DNase I (RNase-Free)
Mar 2, 2026
other
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Mi